cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oncorus Inc
9 own
11 watching
Current Price
$0.11
$0
(3.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2.85M
52-Week High
52-Week High
1.85
52-Week Low
52-Week Low
0.0922
Average Volume
Average Volume
15.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2.85M
icon52-Week High1.85
icon52-Week Low0.0922
iconAverage Volume15.34M
iconDividend Yield--
iconP/E Ratio--
What does the Oncorus Inc do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Oncorus Inc make?
News & Events about Oncorus Inc.
Globe Newswire
2 months ago
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administrationEnded the quarter with $62.2 million...
Globe Newswire
6 months ago
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate ...
Globe Newswire
6 months ago
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 ...
Globe Newswire
8 months ago
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes ...
Globe Newswire
1 year ago
ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics Oncorus is advancing ONCR-021 into clinical development, with IND ...
Frequently Asked Questions
Frequently Asked Questions
What is Oncorus Inc share price today?
plus_minus_icon
Can Indians buy Oncorus Inc shares?
plus_minus_icon
How can I buy Oncorus Inc shares from India?
plus_minus_icon
Can Fractional shares of Oncorus Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Oncorus Inc stocks?
plus_minus_icon
What is today’s traded volume of Oncorus Inc?
plus_minus_icon
What is today’s market capitalisation of Oncorus Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Oncorus Inc?
plus_minus_icon
What percentage is Oncorus Inc down from its 52-Week High?
plus_minus_icon
What percentage is Oncorus Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.11
$0
(3.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SQZ BIOTECHNOLOGIES CO
SQZ BIOTECHNOLOGIES CO
$0.55
$0.00 (0.44 %)
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$2.33
$-0.03 (-1.27 %)
SIGILON THERAPEUTICS INC
SIGILON THERAPEUTICS INC
$4.49
$-0.04 (-0.77 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.31
$-0.07 (-2.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SQZ BIOTECHNOLOGIES CO
SQZ BIOTECHNOLOGIES CO
$0.55
$0.00 (0.44 %)
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$2.33
$-0.03 (-1.27 %)
SIGILON THERAPEUTICS INC
SIGILON THERAPEUTICS INC
$4.49
$-0.04 (-0.77 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.31
$-0.07 (-2.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00